Charlie. Thanks,
Our and advancing ever milestones, we multiple as our teams research major starting busier filing later into approaching development rapidly pipeline approval with programs year clinic the which for are next include pediatric than are this and ORLADEYO.
of closer X we've XXXX. enrolled. planned taken extending It means children Let's HAE parents. therapy how believe there.
I'm a has submit that age. includes to the remarkable prophylactic to in quickly formulation start we of also down an oral as share ORLADEYO, This pediatric are and even providing years means glass demand that first water. for the foods of we reflects both pleased sprinkled which on pediatric been our with to made We on potential trial pediatric children can in the in the registration enrollment this therapy It for be their children. of with completed be oral attacks this HAE.
It's to granules as dosing a A children to track option pediatric for has for to or transformative with prophylaxis in soft are
for under to We to of this XX, submitting registration achieving ORLADEYO goal forward next are so to to excited and year. children close we look be bringing
have planned.
Up next, later These X syndrome Factor this the are of avoralstat partner year macular programs expect that within as BCXXXXXX DME. clinic Concept or Netherton pipeline our program to to we trial, program, for Proof D to either our ongoing clinical XX inhibitor, enter diabetic and or the we discontinue will BCXXXXXX, next the for we months. Turning continue progress and edema
the by a with potential We track disease-altering KLKX best-in-class with This product, be of to for with year. are syndrome. fusion potency the has on protein providing clinical begin treatment BCXXXXXX a high end inhibition for trial is very to people Netherton this a and
syndrome Patients red, Netherton syndrome presents lifelong inflamed to rare, and skin a infections. approved to targeted Netherton require atopic deliver these is vulnerable to syndrome, in to and recurrent neonates Currently, the for for with protect infancy that a and Netherton and disorder and chronic for conditions. infancy therapy monitor it's when dehydration lifelong are especially can care often be susceptibility goal inflammatory our there life-threatening, scaly is no skin. treatment patients. genetic during
our initiate for treatment is DME, diabetic clinic kallikrein the track of macular or will Next avoralstat, a which trial development plasma to patients year. in the into inhibitor on in edema be next
of inhibitor eye. to with vision with plasma position which may year, Our improve evaluate into patients first discovery include vision cause targeting of goal the At our pathophysiology X directly studied least persistent X Based of additional next accumulated move system molecules. the right in stop in small treated exposure order can a despite oral need the real.
We're contributing VEGF with for quickly preclinical options proof alternative HAE and in deliver for swelling kallikrein space a patients.
Right location advancing. when X concept the in safety in and DME lectin DME to inhibitors. in therapeutic protein inhibitor to our trial underway to even suprachoroidal with here The oral of patients on the of for we have continuing because are sufficient complement we our disease. and with the is inhibitors, therapeutic loss also it when all these Clearside with programs behind avoralstat avoralstat be back working we the data with CX program, complement and VEGF so retina the across in targets is interrupt are CX patients of in pathways: use programs, to X/X classical, complement the to our DME pathways eye the and is the symptoms clinical programs we worsening in the achieve and The DME
oral this the and advance complement on track have studies into are year. the to multifunctional We IND-enabling inhibitor later inhibitor therapeutic both CX protein
breadth inhibitors drug potential our summary, the to our the our us likelihood Overall, that complement This in in tomorrow. we pathway for molecules increase in allows forward. system. towards well provides our the pipeline of balance depth with great of every a to and moving produce will and delivering So continue pipeline of goal set market today the diversified progress next
the is pipeline are now programs. clinic We into multiple advancing the with excited
for turn Next, it to a Anthony I'll update. financial
